Supportive Therapies in Ano-Rectal Diseases – Are They Really Useful?

Total Page:16

File Type:pdf, Size:1020Kb

Supportive Therapies in Ano-Rectal Diseases – Are They Really Useful? UDK 616.351/.352-006.04-08 /STRU^NI RAD DOI:10.2298/ACI1003083G Supportive therapies in ano-rectal diseases – Are they really......................................... useful? P. J. Gupta, Fine Morning Hospital and Research Center, D/9, Laxminagar, Nagpur. India. Epidemiological features of proctological disease Ointments containing opiates, xylocain, amethocain, are not well known because available studies have and cinchocain to relieve pain, belladonna to alleviate provided variable conclusions. Risk factors fre- sphincter spasm and silver nitrate to promote healing have quently mentioned include heredity, high socio- all had been in use. These mixtures are introduced either economic level, obesity, smoking, a diet rich in with the finger or through a short rectal bogie to ensure a fats, alcohol, spices and pepper as well low fluid thorough application over the affected part of the anus. rezime intake have all been implicated. Recent reports of topical application of Solcoderm, While treating patients with various ano-rectal pa- Ketanserin gel, eutectic mixtures of 5% Prilocain and 5% thologies, apart from definitive treatment, various ad- Lidocain or combination of Policresulen and Cinchocain ditional or supportive therapies are being advised both have all shown good symptomatic relief in anal pain. 2 by the family physicians and surgeons. These include Topical sucralafte and metronidazole have been found local applications, sitz baths, modification in the diet to reduce pain after hemorrhoidectomy and promoting and life style. But are these supportive therapies really faster wound healing. beneficial or they are just empirical? Some hemorrhoids are associated with high resting anal This paper elaborates the various supportive therapies canal pressures. A topical glyceryl trinitrate 0.2% oint- advocated in the common anal disorders like hemor- ment was effective in relieving symptoms of early grade rhoids, anal fissure and fistula and summarizes the ad- hemorrhoids associated with high resting anal canal pres- vantages and pitfalls of these treatment additives. sures. Key words: suppository, haemorrhoid cream, sitz bath, A topical treatment for hemorrhoidal pain and for diet spasms of the sphincters and muscles containing amino acid L-arginine can be applied directly to the affected INTRODUCTION area. This topical preparation is effective in relieving the pain of hemorrhoids or in treating conditions resulting espite thousands of years and millions of patients from spasms of sphincters of the anal canal including anal Dwith pain, discomfort, and perceived embarrassment fissure and postoperative rectal pain. of ano-rectal disorders, where the exact nature and A rectal cream containing 0.25% oxethacaine chlor-hy- cause of the conditions is quite clear, the standard con- drate has been demonstrated to be clinically efficient in servative treatments are still a matter of debate. the treatment of Grades I and II hemorrhoids as well as in Therapies in vogue such as topical agents, hydrother- post surgical treatment both for the attenuation and elimi- apy, diet, and lifestyle factors are some of the non-inva- nation of pain and the clinical objectives of the pathology sive approaches to these conditions. in question. A heparin and enzyme (trypsin and chymotrypsin) paste Hemorrhoid creams has been reportedly found to improve the sympto-ms by The role of the hemorrhoid topical preparations is to resolution of acutely inflamed hemorrhoids. Topical nifedipine, diltiazem and 1% isosorbide dini- provide temporary relief from hemorrhoidal discomfort, 3 to prevent further irritation, to provide shrinkage of the trate, are few other options in the conservative treatment swollen hemorrhoidal tissue and prompt soothing relief of thrombosed external hemorrhoids. Synthetic Diosmine from painful burning, itching and discomfort.1 has also been used as a topical treatment for acute hemor- 84 P.J. Gupta ACI Vol. LVII rhoids. The treatment is very well tolerated and produces Some common astringents that are used include Hama- no unwanted side effects if properly used. melis water, which is a mild astringent prepared from A mixture of honey, olive oil, and beeswax has been twigs of Hamamelis virginiana. It helps in relief from the found to be clinically effective in the treatment of hemor- hemorrhoidal itch. Zinc oxide prevents the irritation at the rhoids and anal fissure. The honey mixture significantly perianal area by forming a physical barrier on the skin that reduced bleeding and relieved itching in patients with protects the contact of the irritated skin with aggravating hemorrhoids. Patients with anal fissure showed significant liquid or stool from the rectum. reduction in pain, bleeding, and itching after the treat- Vasoconstricting agents help in relieving symptoms of ment. No side effect was reported with use of the mixture. hemorrhoids. On application, these drugs reduce he-mor- These topical preparations should be used with caution rhoidal congestion. These products additionally contain in patients with heart disease, hypertension, thyroid dis- mild form of anesthetic, which helps in relieving pain and ease, diabetes, pregnant or breast-feeding women and pa- itching. The commonly used vasoconstrictors are Ephed- tients having dysurea due to enlarged prostate. The patient rine sulfate and Phenylephrine. should not exceed the recommended daily dosage unless Passing hard and dry stool is the most traumatic experi- directed. Patient is advised to report in case of bleeding or ence in patients having anal pathology as it results in tear- if condition worsens or does not improve within 7 days. ing of the skin around the anus, as also in tearing and These agents may provide short-term relief from anal cracking which ends in bleeding. Again, when this tender discomfort, but there is a lack of evidence to support their skin comes in contact with liquid or stool, it ca-uses the widespread use. They do not affect the underlying patho- skin to further itch and burn. logical changes in the anal cushions. Continuous applica- Protectants, when applied in the form of suppositories, tion can cause eczema and sensitization of the anoderm; form a physical barrier on the skin and results in reducing rectal absorption can lead to systemic side effects. 4 the pain quotient and the pruritus. These also protect the Suppositories - Rectal route is being used effectively in broken skin from coming in contact with offending parti- proctological disorders since time immortal. Drugs mixed cles in the stool. with various adjuvants and administered through the rec- While a variety of protectants are used in suppositories, tal route provide satisfactory pharmacokinetics, which a few commonly used are : have an acceptable local tolerance. Aluminium hydroxide gel, Glycerin, Lanolin, Aloe Suppositories are a medicated solid dosage form in- Vera, White petrolatum, Zinc Oxide and Calamine. tended for insertion into the body orifices. 5 The ano-rec- The anal and perianal skin are susceptible to variety of tal physiology provides a sufficiently adequate surface organisms, which can lodge there either from the adjoin- area for drug absorption. The surface area is also perme- ing area or from the contaminated stool. The chances of able to non-ionized drugs. Suppositories formulations are contamination further increase when the skin gets bruised rather efficient in variety of different bases to increase ab- during defecation. sorption and reduce complications. Antiseptics are used to keep the area clean and to pre- Suppositories come in various sizes and shapes, which vent infection. The commonly incorporated antiseptics in- facilitates their insertion and retention in the cavity. Adult clude- Benzalkonium chloride, Boric Acid and Fra-mycet- rectal suppositories weighed about 2 g while those for ine sulphate. children are about half that weight. Keratolytics are chemicals, which cause the outer layers Suppositories containing local anesthetics agents act by of skin and other tissues to disintegrate when applied. numbing the nerve endings and provide temporary relief They eventually help in better penetration in the tissues of from pain and itching. These act by causing a reversible other medications contained in the suppositories to bring block to conduction in the sensory nerves. These are well quicker relief. The two commonly used keratolytics are absorbed from the mucus membrane and used as surface Aluminium Chlorhydroxy Allantoinate and Resorcinol. anesthetics. These provide good relief from discomfort Policresulen coagulates necrotic or pathogenically al- encountered in cases of strangulated hemorrhoids, fissures tered tissue in anorectal disorder and promotes desqua- and perianal hematomas. mation of such tissues.6 The healthy tissues surrounding Several glucocorticosteroids are used in rectal supposi- the wound are not affected. As a local haemostatic, poly- tories. They include hydrocortisone and its derivatives, di- cresulen coagulates blood proteins thereby inducing mus- flucortolone valerate and predinisolon. The steroids act as cle fibers of small vessels to contract and thus any hemor- decongestant, anti-inflammatory and anti pruritic agents rhage in the anal canal or in the perianal area is controlled. and in doing so they eliminate inflammation and mucus It also induces hyperemia in the wound area and thereby discharge. It has been postulated that the analgesic effects stimulates regeneration and re-epithelization process. It of local anesthetics is apparently
Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Tonsillopharyngitis - Acute (1 of 10)
    Tonsillopharyngitis - Acute (1 of 10) 1 Patient presents w/ sore throat 2 EVALUATION Yes EXPERT Are there signs of REFERRAL complication? No 3 4 EVALUATION Is Group A Beta-hemolytic Yes DIAGNOSIS Streptococcus (GABHS) • Rapid antigen detection test infection suspected? (RADT) • roat culture No TREATMENT EVALUATION No A Supportive management Is GABHS confi rmed? B Pharmacological therapy (Non-GABHS) Yes 5 TREATMENT A EVALUATE RESPONSEMIMS Supportive management TO THERAPY C Pharmacological therapy • Antibiotics Poor/No Good D Surgery, if recurrent or complicated response response REASSESS PATIENT COMPLETE THERAPY & REVIEW THE DIAGNOSIS© Not all products are available or approved for above use in all countries. Specifi c prescribing information may be found in the latest MIMS. B269 © MIMS Pediatrics 2020 Tonsillopharyngitis - Acute (2 of 10) 1 ACUTE TONSILLOPHARYNGITIS • Infl ammation of the tonsils & pharynx • Etiologies include bacterial (group A β-hemolytic streptococcus, Haemophilus infl uenzae, Fusobacterium sp, etc) & viral (infl uenza, adenovirus, coronavirus, rhinovirus, etc) pathogens • Sore throat is the most common presenting symptom in older children TONSILLOPHARYNGITIS 2 EVALUATION FOR COMPLICATIONS • Patients w/ sore throat may have deep neck infections including epiglottitis, peritonsillar or retropharyngeal abscess • Examine for signs of upper airway obstruction Signs & Symptoms of Sore roat w/ Complications • Trismus • Inability to swallow liquids • Increased salivation or drooling • Peritonsillar edema • Deviation of uvula
    [Show full text]
  • Report Name:Ukraine's Mrls for Veterinary Drugs
    Voluntary Report – Voluntary - Public Distribution Date: November 05,2020 Report Number: UP2020-0051 Report Name: Ukraine's MRLs for Veterinary Drugs Country: Ukraine Post: Kyiv Report Category: FAIRS Subject Report Prepared By: Oleksandr Tarassevych Approved By: Robin Gray Report Highlights: Ukraine adopted several maximum residue levels (MRLs) for veterinary drugs, coccidiostats and histomonostats in food products of animal origin. Ukraine also adopted a list of drugs residues that are not allowed in food products. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY The Office of Agricultural Affairs of USDA/Foreign Agricultural Service in Kyiv, Ukraine prepared this report for U.S. exporters of domestic food and agricultural products. While every possible care was taken in the preparation of this report, information provided may not be completely accurate either because policies have changed since the time this report was written, or because clear and consistent information about these policies was not available. It is highly recommended U.S. exporters verify the full set of import requirements with their foreign customers, who are normally best equipped to research such matters with local authorities, before any goods are shipped. This FAIRS Subject Report accompanies other reports on Maximum, Residue Limits established by Ukraine in 2020. Related reports could be found under the following links: 1.) Ukraine's MRLs for Microbiological Contaminants_Kyiv_Ukraine_04-27-2020 2.) Ukraine's MRLs for Certain Contaminants_Kyiv_Ukraine_03-06-2020 Food Products of animal origin and/or ingredients of animal origin are not permitted in the Ukrainian market if they contain certain veterinary drugs residues in excess of the maximum residue levels established in Tables 1 and 2.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Us 2018 / 0344582 A1
    US 20180344582A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0344582 A1 Kim et al. ( 43 ) Pub . Date : Dec . 6 , 2018 ( 54 ) PREPARATION FOR ATTACHING TO Publication Classification TEETH OR SURROUNDING PART OF (51 ) Int. Ci. TEETH A61K 8 / 02 (2006 . 01 ) A61K 8 / 73 ( 2006 .01 ) ( 71 ) Applicant: LG Household & Health Care Ltd . , A61K 8 / 25 ( 2006 .01 ) Seoul (KR ) A61K 8 /69 ( 2006 .01 ) A61K 8 /81 (2006 .01 ) ( 72 ) Inventors : Ji - Young Kim , Daejeon (KR ); A610 11 /00 ( 2006 .01 ) Jae - Hyun Ahn , Daejeon (KR ) ; 2) U . S . CI. Jong -Hoon Kim , Daejeon (KR ) ; In - Ho CPC .. .. .. .. .. A61K 8 /02 ( 2013 . 01 ) ; A61K 8 / 736 Lee , Daejeon (KR ) ; Sang- Min Lee , ( 2013 .01 ) ; A61K 8 / 25 ( 2013 .01 ) ; A61K 9 / 70 Daejeon (KR ) ( 2013 .01 ) ; A61K 8 /69 ( 2013 .01 ) ; A61K 8 /81 ( 2013. 01 ); A61Q 11/ 00 ( 2013 .01 ) ; A61K 8 / 731 ( 73 ) Assignee : LG Household & Health Care Ltd . , (2013 .01 ) Seoul (KR ) (57 ) ABSTRACT The present invention provides a preparation for attaching to ( 21 ) Appl. No. : 15 / 778, 127 teeth or tooth peripheries, which comprises a malleable oral composition and an active ingredient for intra -oral delivery . ( 22 ) PCT Filed : Nov. 10 , 2016 Further, the present invention provides a preparation for attaching to teeth or tooth peripheries , which comprises an ( 86 ) PCT No. : PCT/ KR2016 /012934 oral composition in a hardening ointment -phase and an $ 371 ( c ) ( 1 ) , active ingredient for intra - oral delivery . The preparation of ( 2 ) Date : May 22 , 2018 the present invention may give high adhesive force to the desired site in spite of gaps between teeth or curves of teeth .
    [Show full text]
  • Unduh File PDF
    Majalah Farmasetika, 3 (5) 2018, 98-101 https://doi.org/10.24198/farmasetika.v3i5.21633 e-ISSN : 2686-2506 Perkembangan Obat Sariawan dan Terapi Alternatifnya Prilly Mutiara Sandy*, Fira Burhanisa Irawan Program Studi Sarjana Farmasi, Fakultas Farmasi, Universitas Padjadjaran, Sumedang 45363 email: [email protected] Abstrak : Sariawan merupakan penyakit mulut yang sudah tidak asing lagi. Berbagai kalangan mulai dari balita, remaja, orang tua, maupun lanjut usia tentu pernah mengalami penyakit tersebut. Efek dari sariawan itu sendiri ialah bisa menyebabkan para penderitanya tidak nafsu makan dan mulut terasa perih. Pengobatan yang dapat dilakukan adalah dengan mengonsumsi zat pemati rasa dan antiseptika.Pemakaiannya obat bisa dilakukan sebanyak 2-3 kali dalam sehari. Selain dengan zat pemati rasa, sariawan juga dapat diobati dengan antiseptika. Hasil terbaik dari penggunaan antiseptika terbukti oleh obat kumur provid-ion (Betadine) dan klorheksidin dalam bentuk tablet hisap srta larutan peroksida 3%. Selain itu juga bisa menggunakan obat kumur yang mengandung Chlorhexidine gluconate 2%, sodium hyaluronate, PVP , dan glycyrrhetinic. BPOM menganjurkan penggunaan obat-obat yang memiliki kandungan enzydamine HCL, providone iodine 1%, atau kombinasi dequalinium chloride dan vitamin C. Bagi yang ingin menyembuhkan sariawan dengan bahan-bahan alami, yaitu: tanaman gambir, daun sirih, air garam, dan cabai. Keyword : obat, sariawan, terapi alternative Outline • Pendahuluan • Terapi sariawan • Albothyl (policresulen) • Terapi alternatif • Kesimpulan Pendahuluan Sariawan atau aphtous stomatitis adalah luka yang terdapat di dalam mulut yang biasanya berbentuk oval atau bulat berwarna putih dan dapat menimbulkan rasa tidak sakit serta tidak nyaman. Sariawan disebabkan oleh beberapa hal, diantaranya ialah kurangnya vit C, vit B12 dan bisa juga karena adanya infeksi yang disebabkan oleh bakteri, virus, atau jamur.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • Curettage and Policresulen Tampon As a Modality Treatment in Management of Verucca
    RECONSTRUCTIVE Curettage and Policresulen Tampon as A Modality Treatment in Management of Verucca Huntal Simamora, Puri Ambar Lestari, Kristaninta Bangun, Gentur Sudjatmiko Jakarta, Indonesia. Background: Verruca, also known as warts is a skin disease characterized by epidermal growth. Verruca may occur anywhere especially on palms and soles. It appears as a rough, dark-grey colored surface and has similar features with clavus or callus, which frequently lead to inappropriate management. Patient and Method : We report two cases with verruca, one was on sole and another was on palm area treated with curettage and chemical ablation using policresulen solution. Both cases have histories of recurrences from the previous treatment, which was excision and primary closure. Results : The wound healed within seven days after treatment. There were no recurrences found after 6-month follow up. Summary : Our treatment (curettage and chemical ablation using policresulen) has two advantages: (1) it can avoid excessive tissue removal since this lesion only afect epidermal layer, Pendahuluan: Veruka atau warts adalah kelainan kulit dengan pertumbuhan epidermis yang dapat terjadi di semua kulit tubuh terutama pada telapak tangan dan kaki, dengan tampilan kulit permukaan kasar dan berwarna abu-abu gelap. Ciri-ciri lesi pada veruka yang menyerupai kalus atau klavus sering menyebabkan terjadinya kesalahan penanganan. Pasien dan Metodologi: Kami melaporkan penanganan veruka pada dua kasus. Satu kasus veruka plantaris dua kali residif dan satu kasus veruka palmaris enam kali residif yang sebelumnya ditangani dengan eksisi dan jahit primer. Pada kedua kasus tersebut dilakukan kuretase dan dibakar (ablasi kimia) dengan policresulen. Hasil: Pada evaluasi hari ke-7, didapatkan luka menyembuh dan tidak ditemukan rekurensi pada pengamatan 6 bulan.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0324736A1 Johnson Et Al
    US 20090324736A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0324736A1 Johnson et al. (43) Pub. Date: Dec. 31, 2009 (54) METHODS OF TREATING BOWEL DISEASES (22) Filed: May 7, 2009 BY ADMINISTERING ABOWEL CLEANSER AND AN ANTIBOTC Related U.S. Application Data (60) Provisional application No. 61/051,341, filed on May (75) Inventors: Lorin Johnson, Palo Alto, CA 7, 2008. (US); William Forbes, Raleigh, NC (US); Stephana Patton, San Publication Classification Francisco, CA (US) (51) Int. Cl. Correspondence Address: A633/42 (2006.01) EDWARDS ANGELL PALMER & DODGE LLP A633/14 (2006.01) P.O. BOX SS874 A63L/439 (2006.01) BOSTON, MA 02205 (US) (52) U.S. Cl. .......................... 424/606: 424/679:514/279 (57) ABSTRACT (73) Assignee: Salix Pharmaceuticals, Ltd., Morrisville, NC (US) The present invention relates to formulations and kits for the treatment of bowel disease, to their use in medicinal prepa (21) Appl. No.: 12/437,232 rations and to therapeutic methods thereof. US 2009/032473.6 A1 Dec. 31, 2009 METHODS OF TREATING BOWEL DISEASES 0009. According to one embodiment, the GI cleanser BY ADMINISTERING ABOWEL CLEANSER comprises one or more of a PEG based composition or a AND AN ANTIBOTC Sodium phosphate based composition. 0010. According to one embodiment, the GI cleanser RELATED APPLICATIONS comprises polyethylene glycol (PEG), sodium sulfate, 0001. This application claims the benefit of U.S. Provi Sodium chloride, potassium chloride, and ascorbic acid. sional Application No. 61/051,341, filed May 7, 2008, the 0011. According to one embodiment, the GI cleanser is entire contents of which is expressly incorporated herein by supplied as two pouch A's comprising 100 grams of PEG reference.
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]
  • The Ministry of Agriculture, Fisheries and Rural Development
    THE MINISTRY OF AGRICULTURE, FISHERIES AND RURAL DEVELOPMENT Pursuant to Article 15, paragraph 1, subparagraph 2 of the Food Act (Official Gazette 46/07) and Article 87, paragraph 6 of the Veterinary Act (Official Gazette 41/07), the Minister of Agriculture, Fisheries and Rural Development hereby issues the ORDINANCE ON MAXIMUM RESIDUE LIMITS OF VETERINARY MEDICINAL PRODUCTS IN FOODSTUFFS OF ANIMAL ORIGIN 1 Article 1 1) This Ordinance lays down the maximum residue limits of veterinary medicinal products (hereinafter: VMP) in foodstuffs of animal origin. (2) This Ordinance shall not apply to active principles of biological origin intended to produce active or passive immunity or to diagnose a state of immunity used in immunological VMPs. (3) This Ordinance shall not prejudice the application of special regulations prohibiting the use in livestock farming of certain substances having a hormonal action nor shall it prejudice the measures taken to prevent the unauthorised use of VMPs. Definitions Article 2 1) For the purposes of this Ordinance, the following definitions shall apply: (a) ‘residues of veterinary medicinal products’ means all pharmacologically active substances, whether active principles, excipients or degradation products, and their metabolites which remain in foodstuffs obtained from animals to which the VMP in question has been administered; b) ‘maximum residue limit’ (hereinafter: MRL) means the maximum concentration of residue resulting from the use of a VMP (expressed in mg/kg or µg/kg on a fresh weight basis) which may be legally permitted or recognised as acceptable in or on a food. MRL is based on the type and amount of residue considered to be without any toxicological hazard for human health as expressed by the acceptable daily intake, or on the basis of a temporary acceptable daily intake that utilises an additional safety factor.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]